Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Inclusion Criteria: * Previously untreated non-cutaneous peripheral T-cell lymphoma, including human T-cell lymphotropic virus type 1 (HTLV-1) related T-cell lymphoma, and natural killer (NK)-cell lymphoma. * Ages 18 to 65 years. * Life expectancy \> 3 months. * Written informed consent. Exclusion Criteria: * B-cell lymphoma or other subtype of T-cell lymphoma including anaplastic large cell lymphoma AKL(+), lymphoblastic lymphoma and primary cutaneous T-cell lymphoma. * Any previous therapy for lymphoma except for short-term corticosteroids before inclusion. * Inability to tolerate the ACVBP regimen according to investigator's judgement. * Positive serology for HIV. * Poor renal function (creatinin \> 150 µmol/l within 14 days before enrollment), poor liver function (total bilirubin \> 30 µmol/l, transaminases \> 2.5 upper normal limit \[UNL\] within 14 days before enrollment), unless these abnormalities are related to the lymphoma. * Poor bone marrow reserve as defined by neutrophils \< 1.5 G/l or platelets \< 100 G/l within 14 days before enrollment, unless these abnormalities are related to the lymphoma. * Patient with \>= grade 2 peripheral neuropathy non-related to lymphoma. * Any central nervous system (CNS) disease. * CNS or meningeal involvement by the lymphoma. * Any serious active disease or comorbidity according to the investigator's decision. * Any history of cancer during the last 5 years with the exception of non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma. * Known hypersensitivity to bortezomib, boron or mannitol. * Contraindication to any cytotoxic drug contained in chemotherapy regimen. * Pregnant or lactating women or women of childbearing potential not willing to use an adequate method of birth control (i.e. hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of study. * Men not agreeing to take adequate contraceptive precautions during the study. * Treatment with investigational drug within 30 days before planned first cycle of chemotherapy and during the study. * Adult patient under tutelage.